Correction: A Phase I Study of the Heat Shock Protein 90 Inhibitor Alvespimycin (17-DMAG) Given Intravenously to Patients with Advanced Solid Tumors

In the original version of this article (1), Fig. 3A included duplicate gel lanes for the third patient from the left and mislabeled lanes for the fifth patient from the left. The authors contacted the Editors and provided original images to correct the figure. Errors have been corrected in the latest online HTML and PDF versions of the article. The authors regret these errors.